Sino Biopharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Sino Biopharmaceutical has a total shareholder equity of CN¥38.2B and total debt of CN¥12.3B, which brings its debt-to-equity ratio to 32.3%. Its total assets and total liabilities are CN¥63.6B and CN¥25.4B respectively. Sino Biopharmaceutical's EBIT is CN¥5.4B making its interest coverage ratio -46.8. It has cash and short-term investments of CN¥14.1B.
Key information
32.3%
Debt to equity ratio
CN¥12.35b
Debt
Interest coverage ratio | -46.8x |
Cash | CN¥14.12b |
Equity | CN¥38.17b |
Total liabilities | CN¥25.43b |
Total assets | CN¥63.60b |
Recent financial health updates
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28Recent updates
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Financial Position Analysis
Short Term Liabilities: 1177's short term assets (CN¥23.8B) exceed its short term liabilities (CN¥22.6B).
Long Term Liabilities: 1177's short term assets (CN¥23.8B) exceed its long term liabilities (CN¥2.8B).
Debt to Equity History and Analysis
Debt Level: 1177 has more cash than its total debt.
Reducing Debt: 1177's debt to equity ratio has increased from 9.1% to 32.3% over the past 5 years.
Debt Coverage: 1177's debt is well covered by operating cash flow (49.1%).
Interest Coverage: 1177 earns more interest than it pays, so coverage of interest payments is not a concern.